Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial
Authors:
- Tzu-Hsien TsaiTTTzu-Hsien Tsai
- Cheng-Hsien LuCLCheng-Hsien Lu
- Christopher Glenn WallaceCWChristopher Glenn Wallace
- Wen-Neng ChangWCWen-Neng Chang
- Shu-Feng ChenSCShu-Feng Chen
- Chi-Ren HuangCHChi-Ren Huang
- Nai-Wen TsaiNTNai-Wen Tsai
- Min-Yu LanMLMin-Yu Lan
- Pei-Hsun SungPSPei-Hsun Sung
- Chu-Feng LiuCLChu-Feng Liu
- Hon-Kan YipHYHon-Kan Yip
Open Access
- 25 February 2015
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-9
Abstract
Introduction: Mortality and disability following ischemic stroke (IS) remains unacceptably high with respect to the conventional therapies. This study tested the effect of erythropoietin (EPO) on long-term neurological outcome in patients after acute IS. This study aimed to evaluate the safety and efficacy of two consecutive doses of EPO (5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS) on improving the 90-day combined endpoint of recurrent stroke or death that has been previously reported. A secondary objective was to evaluate the long-term (that is, five years) outcome of patients who received EPO.Methods: This was a prospective, randomized, placebo-controlled trial that was conducted between October 2008 and March 2010 in a tertiary referral center. IS stroke patients who were eligible for EPO therapy were enrolled into the study.Results: The results showed that long-term recurrent stroke and mortality did not differ between group 1 (placebo-control; n = 71) and group 2 (EPO-treated; n = 71).Long-term Barthel index of P = 0.007). Multiple-stepwise logistic-regression analysis showed that EPO therapy was significantly and independently predictive of freedom from a Barthel index of P = 0.029). Long-term major adverse neurological event (MANE; defined as: death, recurrent stroke, or long-term Barthel index < 35) was lower in group 2 than group 1 (P = 0.04). Log-Rank test showed that MANE-free rate was higher in group 2 than group 1 (P = 0.031). Multiple-stepwise Cox-regression analysis showed that EPO therapy and higher Barthel Index at day 90 were independently predictive of freedom from long-term MANE (allP<0.04).Conclusion: EPO therapy significantly improved long-term neurological outcomes in patients after IS.Trial registration: ISRCTN71371114. Registered 10 October 2008.Keywords
This publication has 44 references indexed in Scilit:
- Assessment scales in stroke: clinimetric and clinical considerationsClinical Interventions in Aging, 2013
- Estimated Glomerular Filtration Rate as a Useful Predictor of Mortality in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionThe American Journal of the Medical Sciences, 2013
- The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness studyBMC Neurology, 2012
- Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic strokeCritical Care, 2011
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic StrokeStroke, 2009
- Hypoxic preconditioning protects rat hearts against ischaemia–reperfusion injury: role of erythropoietin on progenitor cell mobilizationThe Journal of Physiology, 2008
- Long-Term Fatal Outcomes in Subjects With Stroke or Transient Ischemic AttackStroke, 2008
- Level and Value of Circulating Endothelial Progenitor Cells in Patients After Acute Ischemic StrokeStroke, 2008
- Comparison of Neurological Scales and Scoring Systems for Acute Stroke PrognosisStroke, 1996
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993